研究单位：[1]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[2]Southwest Hospital, China[3]Women Hospital, School of Medicine, Zhejiang University[4]Anhui Provincial Cancer Hospital[5]Sichuan Cancer Hospital and Research Institute[6]Gansu Provincial Maternal and Child Health Care Hospital[7]Beijing Friendship Hospital[8]Tianjin Medical University General Hospital[9]Xiangya Hospital of Central South University[10]West China Second University Hospital[11]Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University[12]Zhejiang Cancer Hospital[13]Shengjing Hospital[14]Qilu Hospital of Shandong University
研究目的：
This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.
